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[11C]PBR28 binds the 18-kDa Translocator Protein (TSPO) and is used in positron emission
tomography (PET) to detect microglial activation. However, quantitative interpretations of signal are
confounded by large interindividual variability in binding affinity, which displays a trimodal distribution
compatible with a codominant genetic trait. Here, we tested directly for an underlying genetic
mechanism to explain this. Binding affinity of PBR28 was measured in platelets isolated from 41 human
subjects and tested for association with polymorphisms in TSPO and genes encoding other proteins in
the TSPO complex. Complete agreement was observed between the TSPO Ala147Thr genotype and
PBR28 binding affinity phenotype (P value=3.11013). The TSPO Ala147Thr polymorphism predicts
PBR28 binding affinity in human platelets. As all second-generation TSPO PET radioligands tested
hitherto display a trimodal distribution in binding affinity analogous to PBR28, testing for this
polymorphism may allow quantitative interpretation of TSPO PET studies with these radioligands.
Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1–5; doi:10.1038/jcbfm.2011.147; published online
19 October 2011
Keywords: Ala147Thr; PBR28; polymorphism; radioligand binding; TSPO
Introduction
The 18-kDa Translocator Protein TSPO (also called the
Peripheral Benzodiazepine Receptor) is expressed
within monocyte-derived cells and has been proposed
as a marker of brain microglial activation (Venneti
et al, 2006). Quantitative imaging of TSPO with
positron emission tomography (PET) has been techni-
cally challenging. The poor signal-to-noise ratio and
high nonspecific binding of the first-generation ligand
[11C]PK11195 limit accurate quantification (Banati
et al, 2000). Several second-generation TSPO ligands
with improved signal-to-noise ratio, including
[11C]PBR28, [18F]PBR06, [18F]FEPPA, [11C]DAA1106,
[11C]DPA713, and [18F]PBR111, have been investigated
in human (Chauveau et al, 2008).
However, PET (Kreisl et al, 2010) and recent
in-vitro studies have revealed substantial heteroge-
neity in binding potential due to intersubject
variability in the affinity of the second-generation
PET ligands for the TSPO (Owen et al, 2010, 2011a).
These tracers bind TSPO in brain tissue from
different subjects in one of three ways: high-affinity
binders and low-affinity binders (HABs and LABs)
express a single binding site for TSPO with either
high or low affinity, respectively, whereas mixed
affinity binders (MABs) express approximately equal
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numbers of the HAB and LAB binding sites (Owen
et al, 2011a). Subjects remain in the same binding
class regardless of which second-generation radio-
ligand is used for classification, although the exact Ki
values of the binding classes vary between ligands
(Owen et al, 2011a). For example, PBR28 Ki values
for HABs and LABs are 4 and 200nmol/L, respec-
tively, whereas for PBR111 these values are 16 and
62nmol/L. Prior knowledge of binding affinity,
therefore, is required for quantitative comparisons
of TSPO expression between subjects in PET studies
with these radioligands. This may not be necessary
for [11C]PK11195 as in-vitro studies suggest that this
radioligand binds to a different site on the TSPO,
with no apparent difference in affinity between
HABs and LABs (Owen et al, 2010).
The mechanisms responsible for the different TSPO
binding behaviors are not understood. Based on our
data which suggests that MABs appear to express the
HAB and LAB sites in equal proportion (Owen et al,
2011a), we hypothesized that codominant expression
of an underlying genetic trait explains variation in
binding phenotype and that this behavior could arise
from polymorphisms in either TSPO or other genes
encoding proteins in the TSPO complex.
Here, we present the results of a genetic association
study between PBR28 binding affinity to human
platelets and polymorphisms in genes encoding TSPO
and associated proteins. Our work provides the basis
for a simple genetic test for determination of TSPO
binding class, which will contribute to quantitative
interpretation of PET studies of TSPO expression.
Materials and methods
The study protocol, volunteer information, and informed
consent forms were approved by the North West London
Research Ethics Committee. Forty-one healthy volunteers (29
male, 12 female, mean age 36.3±1.4 years) were recruited.
Ethnicity was self-reported as 37/41 Caucasian, 2/41 Asian,
1/41 mixed Caucasian/Asian, and 1/41 Hispanic. Venous
blood (50ml) was drawn into EDTA-containing tubes, and
separated into a lymphocyte-rich bottom layer (for genetic
analysis) and platelet-rich top layer by centrifugation (180 g,
15min, room temperature (RT)). The platelet-rich layer (for
binding assays) was re-centrifuged (1800 g, 15min, RT) to
produce a platelet-containing pellet. Platelet membranes were
prepared as previously described (Owen et al, 2011a). To
measure binding affinity, aliquots of membrane suspension
were incubated with 5nmol/L [3H]PK11195 (Perkin-Elmer,
Beaconsfield, UK) and one of 12 concentrations (0.1nmol/L
to 100mmol/L) of unlabelled PBR28 (Borochem, Caen, France)
as previously described (Owen et al, 2011a).
DNA Extraction
Genomic DNAwas extracted (by Gen-Probe, Manchester, UK)
from B20ml of lymphocyte-enriched blood product (see
membrane preparation) using a chlorinated DNA extraction
protocol and resuspended in 10mmol/L Tris/0.1mmol/L
EDTA pH 8.0. Twenty nanograms of each genomic DNA
sample was plated and lyophilized in a 96-well microtiter
plate for each polymorphism tested. All samples were
duplicated on each plate as a quality control measure.
Polymorphism Selection and Genotyping
A total of 58 polymorphisms (both single nucleotide changes
and insertions/deletions) with a perceived effect on protein
function were selected from known polymorphisms in the
TSPO gene and in genes encoding proteins directly
associated with TSPO in the TSPO complex (VDAC1,
VDAC2, VDAC3, ANT (SLC25A4), PRAX1 (BZRAP1), and
PAP7 (ACBD3)) (Supplementary Table 1). The polymorph-
isms were genotyped using TaqMan (Applied Biosystems,
Foster City, CA, USA), Luminex-based Flow Assorted SNP
Typing (Taylor et al, 2001), direct sequencing or PCR
fragment analysis (see Supplementary Methods for more
details on assay conditions and quality control measures). Of
the 58 genotyped polymorphisms, 38 were found to be
monomorphic in the study sample; therefore, only 20
polymorphisms were analyzed for association with the
ligand binding phenotype (Supplementary Table 1).
Data Analysis
Platelet binding affinity: Binding data were analyzed using
GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA,
USA). Single site and two site competition models were
fitted using the least squares algorithm and model selection
was compared using an F test. The null hypothesis, that the
data fitted a single site model, was rejected if the P value was
<0.05. A Kd for [
3H]PK11195 of 29.25nmol/L (Owen et al,
2010) was used to generate the Ki for PBR28. HABs and LABs
were defined as subjects with a single binding site with Ki
< 15 or >100nmol/L, respectively. MABs were defined as
subjects with two binding sites. Data are expressed as the
mean±standard error of the mean.
Genetic Polymorphisms
The PBR28 ligand binding classification end point was
analyzed using three groups: LABs, MABs, and HABs.
Single marker analysis was performed by Fisher’s exact test
using SAS 9.2 (Cary, NC, USA). The two-tailed P value and
estimated odds ratio with 95% confidence interval were
calculated. A 5% significance threshold was used by
applying a Bonferroni correction for the number of markers
analyzed (n=20) (significance threshold P=0.0025). Link-
age disequilibrium analysis (VanLiere and Rosenberg,
2008) and departure from Hardy–Weinberg Equilibrium
(Wigginton et al, 2005) were tested on data from Caucasian
subjects. See Supplementary Methods for more detail.
Results
Binding Class
Protein in platelets from 27/41 subjects (66%)
showed ligand binding to a single class of high
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DR Owen et al
2
Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1–5
affinity sites (Ki = 2.17±0.17nmol/L). These subjects
were classified as HABs. In 12/41 subjects (29%), the
data fitted best to a two site model with affinities of
2.23±0.31 and 297±43nmol/L. These subjects were
classified as MABs. In the remaining 2/41 subjects
(5%), the ligand bound to a single class of low
affinity sites (Ki = 187±20nmol/L). These subjects
were classified as LABs (Figure 1A).
Genetic Polymorphisms
Single marker analysis revealed that only one
polymorphism (rs6971) surpassed the multiple test-
ing P value threshold of 0.0025 (Supplementary
Figure 1a; Supplementary Table 1). This polymorph-
ism is located in exon 4 of the TSPO gene and is
predicted to result in a nonconservative amino-acid
substitution at position 147 from alanine to threo-
nine (Ala147Thr) in the fifth transmembrane domain
of the TSPO protein. Complete agreement was
observed between the PBR28 binding phenotype
for individual subjects and their rs6971 genotype
(P value 3.1 1013; Table 1; Figure 1B). A linkage
disequilibrium plot for the five TSPO markers
analyzed indicated that the low level of linkage
disequilibrium (Supplementary Figure 1b) could
account for the weak, statistically nonsignificant
associations observed for flanking TSPO polymor-
phisms, rs3937387 and rs6972 (Supplementary
Figure 1a). This pattern of association is what would
be expected for a codominant monogenic trait.
Discussion
Here, we demonstrate complete agreement between
TSPO binding affinity class measured in human
platelets with PBR28, and variation at a common
polymorphism (rs6971) in the TSPO gene which
leads to an amino-acid substitution (Ala147Thr).
These data indicate that variation in binding affinity
of PBR28 for human platelets is a codominant
monogenic trait.
This finding is highly significant for the inter-
pretation of PET studies using [11C]PBR28. We have
not formally demonstrated concordance in binding
class between platelets and brain or other organs, but
agreement seems highly likely as PET data with
[11C]PBR28 strongly suggests that the LAB phenotype
is consistent across all tissues within the same
subject (Kreisl et al, 2010). We, therefore, believe
that PBR28 binding affinity class in the brain (or
other tissues) can be predicted simply by genotyping
the TSPO rs6971 polymorphism. In the absence of an
available TSPO radioligand which binds with
equivalent affinity in all subjects and has a high
signal-to-noise ratio, genotyping the TSPO rs6971
polymorphism will enable confident, quantitative
comparisons of [11C]PBR28 PET data between groups
of patients. This can be achieved either by screening
out certain subjects to ensure all study participants
are from the same binding class, or by including all
subjects but correcting PET data based on binding
class.
Our results have the same implications for
PET studies using [18F]PBR06, [11C]DAA1106,
Figure 1 (A) Competition binding assay using unlabelled PBR28
to displace [3H]PK11195 in human platelets isolated from
whole blood (n=41). The dashed vertical line indicates the
concentration of PBR28 used to generate panel B. The fractional
binding is described by the following equations,
One site model
B ¼ ð1NSÞ Ki
Ki þ ½PBR28 þNS
Two site model
B ¼ ð1NSÞ fHK
H
i
KHi þ ½PBR28
þ ð1 fHÞK
L
i
KLi þ ½PBR28
 
þNS
where B, binding signal; NS, nonspecific binding; Ki, binding
affinity; and fH, the fraction of high-affinity binding sites.
(B) Box-whisker plot of the residual [3H]PK11195 binding in
the presence of 100 nmol/L unlabelled PBR28 (expressed as a
percentage of the total [3H]PK11195 binding in the absence of
PBR28) stratified on rs6971 genotype. Percentage residual of
total binding is plotted as blue diamonds for each individual.
HAB, high affinity binder; LAB, low affinity binder; MAB, mixed
affinity binder.
TSPO polymorphism and PBR28 binding affinity
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[11C]DPA713, [18F]PBR111, and [11C]AC-5216.
Although there is no data confirming that these
ligands bind at the same site as [11C]PBR28, we have
previously demonstrated that binding class shows
complete consistency between radioligands; in other
words, all tissue samples classified as HABs with
PBR28 are also classified as HABs with the other
radioligands (Owen et al, 2011a).
The results also could help to better understand
pharmacokinetic–pharmacodynamic relationships
for drugs targeting TSPO, as we have suggested
previously based on data from direct binding affinity
assays with XBD173 (AC-5216) (Owen et al, 2011b).
This binding affinity variation has greatest impact
for studies of Caucasians, for whom the rs6971
polymorphism has a reported minor allele (Thr147)
frequency of 30% and a major allele (Ala147)
frequency of 70% (11). The minor allele is less
prevalent in other populations, such as African
American (25%), Han Chinese (2%), and Japanese
(4%) (http://hapmap.ncbi.nlm.nih.gov/cgi-perl/snp_
details_phase3?name = rs6971&source = hapmap28_
B36&tmpl = snp_details_phase3). In our small
predominantly Caucasian sample, the observed
percentage of MABs and LABs (29% and 5%, respec-
tively) was lower than expected (42% and 9%,
respectively) based on published frequencies,
although they are not outside the 95% confidence
bounds for sampling variation. This discrepancy
could be explained by some subjects inaccurately
reporting their own ancestral background, or the
result of an unknown bias in ascertainment.
Structural modelling using a general platform in
wide use (PolyPhen software; Ramensky et al, 2002)
suggests that substitution of threonine (neutral and
polar) for alanine (neutral and hydrophobic) at
position 147 of TSPO could alter the protein tertiary
structure (PolyPhen score 0.999, data not shown).
Alanine 147 is highly conserved across most species
(Murail et al, 2008), and likely contributes to
maintaining the helical structure of the fifth trans-
membrane domain of the protein. Protein structure
data based on mouse and bacterial TSPO suggest that
this helical conformation could have a key role in
TSPO function (Korkhov et al, 2010; Murail et al,
2008). We, therefore, hypothesize that the Ala147Thr
amino-acid substitution results in a conformational
change affecting the interaction between TSPO and
the variety of molecules for which affinity differ-
ences have been demonstrated (Owen et al, 2010,
2011a, b).
There is some evidence suggesting that the
Ala147Thr substitution has an impact on biological
functions of TSPO. An association between the
polymorphism and variation in pregnenolone pro-
duction and plasma levels of LDL cholesterol has
been reported in healthy individuals (Costa et al,
2009a). A small pilot study in patients with a
diagnosis of depression also found an association
between the polymorphism and separation anxiety
(Costa et al, 2009b). However, neither of these
findings has been replicated yet.
While the relatively small size of our sample is a
potential limitation of this study, the perfect con-
cordance between binding affinity class and the
rs6791 polymorphism is striking. Direct testing of
the relationships between genetic variation, platelet
binding and [11C]PBR28 PET signal in vivo is needed
now.
The relative affinity of the PET radioligand
[11C]PBR28 for TSPO in human platelets is deter-
mined by a single polymorphism (rs6971) in the
TSPO gene. Our results, therefore, suggest that a
simple test of genotype will enable determination of
TSPO ligand binding class to allow quantitative
assessments of TSPO density using PET.
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